TRN 157

Drug Profile

TRN 157

Alternative Names: TRN-157

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theron Pharmaceuticals
  • Class Antiasthmatics; Antibronchitics; Bronchodilators
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma
  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Sep 2017 TRN 157 is still in phase II trials for Asthma in USA
  • 01 Mar 2016 Theron Pharmaceuticals completes a phase II trial in Asthma in USA (Inhalation) (NCT02382510)
  • 01 Feb 2015 Phase-II clinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top